Buprenorphine, an evidence-based treatment for opioid use disorder, is currently underprescribed because of concerns that it can cause “precipitated withdrawal,” in which the first dose causes sudden, intense pain and anxiety that resolves within a few hours. A new review of the best available evidence has found that the rate of buprenorphine-precipitated withdrawal in adults with opioid use disorder is low and should not be a barrier to use.
This article was originally published on MedicalXpress.com
